CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, in dasatinib treated CML patients we have earlier reported that majority of CD8+ T-cells are CD45RO+[35] and this phenotype is related to better therapy outcome [26], [36].